longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Seelos Therapeutics

SEEL

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current Valuation

--P/E
--Stock price
--P/E
Stock price--

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0285684112

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-55.25x14.01%$57.69B
BAYZFUSBayer Aktiengesellschaft
-27.51x--$55.50B
BAYRYUSBayer
-27.17x--$54.82B
VTRSUSViatris
-46.17x110.35%$18.96B
ELANUSElanco Animal Health
-58.17x129.36%$11.58B
AXSMUSAxsome Therap
-60.34x27.32%$11.56B
VREOFUSVIREO GROWTH INC
-169.84x--$11.40B
CURLFUSCuraleaf Holdings, Inc.
-140.80x--$7.33B
BLTEUSBelite Bio
-68.37x29.87%$7.00B
DFTXUSDefinium Therapeutics
-14.77x53.67%$5.23B
EWTXUSEdgewise Therapeutics
-24.45x137.29%$4.82B
MANEUSVeraDermics
-39.65x97.39%$4.13B
ELVNUSEnliven Therapeutics
-37.57x1.17%$3.98B
AMLXUSAmylyx Pharmaceuticals
-26.09x1.76%$3.97B
TARSUSTarsus Pharmaceuticals
-74.89x34.09%$3.48B
MBXUSMBX Biosciences
-27.25x32.19%$2.84B
RGCUSRegencell Bioscience
-396.46x--$2.79B
GPCRUSStructure Therapeutics
-12.83x104.48%$2.76B
ATAIUSAtaiBeckley
-4.08x86.86%$2.73B
PHVSUSPharvaris BV
-13.45x7.47%$2.67B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.